A synthesis of the PMCHS framework as it stands today — its central proposition, its four pillars, and the general interoceptive hypoesthesia hypothesis.
The Programmed Mast Cell Hyperreactivity Syndrome (PMCHS) designates a heritable biological terrain in which mast cells — sentinel cells of the immune system — exhibit a chronically lowered activation threshold. This dysregulation is programmed: it results from the interaction between genetic predisposition, perinatal stress exposure, and epigenetic amplifiers transmissible across generations.
Unlike mast cell activation syndromes (MCAS) as currently defined, PMCHS presents not as an isolated pathology but as a transversal mechanism — a common underlying denominator across conditions as diverse as lipedema, PCOS, sudden infant death syndrome, autism spectrum disorders, ADHD, PTSD, fibromyalgia, and long COVID.
The term"idiopathic" — without known cause — no longer reflects what scientific and epidemiological data consistently shows. PMCHS proposes a coherent mechanistic framework where specialized medicine still sees only silos.
Predominantly transmitted along the maternal line, consistent with an epigenetic profile. Maternal-to-paternal ratio of 5.4:1 in survey data (N=423).
ERα/GPR30 → mast cell activation → histamine + LTC4 → endothelial HMGB1 → mast cell activation via RAGE. A self-sustaining cycle specific to the role of estrogen in tissue inflammation, notably in the pathogenesis of lipedema and obesity. See the loop diagram.
Early stress and childhood trauma dysregulate the HPA axis and durably lower the mast cell reactivity threshold via NR3C1 methylation — programming the terrain for decades ahead.
The same underlying terrain expresses itself differently depending on target organs: adipose, vascular, neurological, reproductive — explaining chronic multi-system symptomatology.
Distinct from the estrogenic amplification loop above — which acts locally on tissue inflammation — a second, transgenerational mechanism may explain the worsening of the PMCHS terrain from generation to generation. It combines four factors that accumulate: mitochondrial transmission along the maternal line (5.4:1 ratio, consistent with the "Maternal transmission" pillar above), epigenetic amplification (NR3C1/KITLG methylation), combined parental load, and fetal microchimerism — the residual semi-allogeneic cells that persist in maternal tissues after a pregnancy and may program the mast cell terrain of the next child. See the transgenerational burden diagram.
Since summer 2026, the causal model has been restructured around a more parsimonious principle: the locus coeruleus (chronic hyperactivation) as the central upstream node, from which four branches of observable consequences flow — mast cell/immune dysregulation, general interoceptive hypoesthesia (GIH), behavioral regulation mechanisms (dissociation, fawning), and residual archaic reflexes. The origin of the terrain itself is now positioned upstream of the locus coeruleus, on the side of an early rupture of safety and attachment rather than generic perinatal trauma.
In PMCHS, chronic excess histamine progressively desensitises H1 receptors in the hypothalamus — the central organ that integrates all the body's homeostatic signals. The result: a functional blindness to internal signals, independent of willpower and invisible on standard clinical examination.
The same hypothalamic pulsatile logic applies to the somatotropic axis: GHRH, like TRH, depends on intact hypothalamic signaling for its nocturnal pulsatile secretion. Chronic H1 desensitization could therefore also blunt GH secretion and, consequently, IGF-1 — potentially resulting in slowed growth or adult height slightly below genetic potential. This remains a non-systematic hypothesis, to be confirmed with cohort data (height, childhood growth velocity).
This is not a primary neurological disorder. It is the same mechanism by which any receptor chronically exposed to its ligand eventually reduces its sensitivity — adaptive down-regulation with concrete consequences on daily life.
The good news: under mast cell stabilisation (quercetin, luteolin, cromoglycate), progressive re-sensitisation of hypothalamic H1 receptors is possible. The return of functional satiety after treating the underlying terrain constitutes one of the first clinical validations of this hypothesis.
⚗️ Original hypothesis — mechanistic components published (Goldstein & Halperin 1977; Li et al. 2025), application to PMCHS terrain: E. Silva 2026. Formal documentation in progress.